Released Nov 10, 2026, after the close
10-Q filed Nov 10, 2026, 41 days after period end · 0001193125-26-455455
SAN DIEGO, November 10, 2026 – Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today reported third quarter 2026 financial results and provided a corporate update.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $22.84M | $20.75M | — | — |
| Net Income | -$70.22M | -$74.12M | -$54.40M |
Kura Oncology, Inc. · CIK 1422143 · Engraved from SEC EDGAR
| -$38.60M |
| EPS Diluted | -$0.78 | -$0.85 | -$0.63 | -$0.50 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kura reported third quarter 2026 KOMZIFTI net product revenue of $13.9 million, a 53% increase from 2Q 2026, and approximately 150 new patient starts, a 30% increase.¶2¶3
Kura entered into a strategic financing agreement with affiliates of Oberland Capital providing up to $300 million, and received $55 million at closing.¶4¶5
As of September 30, 2026, Kura had $492.1 million in cash, cash equivalents and short-term investments, compared with $667.2 million as of December 31, 2025.¶6
Kura updated its 2026 collaboration revenue guidance to $40 million to $45 million.¶7